Recombinant CA9 (Girentuximab Biosimilar) antibody

Catalog No. ABIN7581268

The Human Monoclonal anti-CA9 (Girentuximab Biosimilar) antibody has been validated for ELISA, FACS, BLI, Func and SPR. It is suitable to detect CA9 (Girentuximab Biosimilar) in samples from Human.

Quick Overview for Recombinant CA9 (Girentuximab Biosimilar) antibody (ABIN7581268)

Target: CA9 (Girentuximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Human

Clonality: Monoclonal

Conjugate: This CA9 (Girentuximab Biosimilar) antibody is un-conjugated

Application: ELISA, Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)

Product Details anti-CA9 (Girentuximab Biosimilar) Antibody

Expression System: CHO Cells

Purpose: Anti-CA9 / CAIX Reference Antibody (girentuximab)

Sequence: DVKLVESGGG LVKLGGSLKL SCAASGFTFS NYYMSWVRQT PEKRLELVAA INSDGGITYY LDTVKGRFTI SRDNAKNTLY LQMSSLKSED TALFYCARHR SGYFSMDYWG QGTSVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK,DIVMTQSQRF MSTTVGDRVS ITCKASQNVV SAVAWYQQKP GQSPKLLIYS ASNRYTGVPD RFTGSGSGTD FTLTISNMQS EDLADFFCQQ YSNYPWTFGG GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC

Characteristics: Anti-CA9 / Carbonic anhydrase 9 Reference Antibody (girentuximab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.

Purity: >95 %

Isotype: IgG1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Therapeutic Agents by Target and Mechanism: CAIX inhibitors

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: 1 mg/mL

Buffer: 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2

Storage: 4 °C,-80 °C

Storage Comment: +4°C,-80°C

Target Details for CA9 (Girentuximab Biosimilar)

Target: CA9 (Girentuximab Biosimilar)

Target Type: Biosimilar

Molecular Weight: 145.5 kDa

UniProt: Q16790